A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD)
- Study Title
- A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD)
- Teva Identifier
- TV48574-IMM-20036
- ClinicalTrials.gov Identifier
- NCT05499130
- Study Status
- Completed
- Trial Condition(s)
- Crohn Disease|Colitis, Ulcerative
- Interventions
- Drug: TEV-48574 | Drug: Placebo
- EudraCT Number
- 2021-006881-19
- EU CT Number
- 2024-511089-36-00
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years to 75 Years
- Trial Duration
- September 30, 2022 - November 12, 2024
- Phase
- Phase 2